Orange Book product · Brand (NDA)
EXELON
RIVASTIGMINE
At a glance
Aug 31, 2012
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 31, 2012
14 yr ago
Today
Pharmaceutical detail
Active ingredient
RIVASTIGMINE
Strength
13.3MG/24HR
Dosage form
FILM, EXTENDED RELEASE
Route
TRANSDERMAL
TE code
AB
Application
NDA 022083
Product number
005
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2025RIVASTIGMINEGeneric (ANDA)
ANDA 215445 · YICHANG HUMANWELL
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 209063 · BRECKENRIDGE
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 206318 · ZYDUS PHARMS
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 207308 · AMNEAL PHARMS
- 2018RIVASTIGMINEGeneric (ANDA)
ANDA 205622 · MYLAN TECHNOLOGIES
- 2015RIVASTIGMINEGeneric (ANDA)
ANDA 204403 · ALVOGEN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
